化学
癌症研究
纳米技术
细胞生物学
姜黄素
转移
肿瘤细胞
药品
生物物理学
药物输送
分子成像
纳米颗粒
超分子化学
计算生物学
纳米医学
药物发现
细胞毒性
核成像
活性氧
生物化学
化学生物学
表观遗传学
荧光寿命成像显微镜
荧光
肿瘤微环境
靶向给药
癌症
分子探针
作者
Rujing Wang,Lan Zou,Dandan Mi,Chuan Wang,Zijian Song,Tiantian Liu,Mengnan Zhao,Dong Wang,Sanjun Shi
标识
DOI:10.1016/j.mtbio.2026.103681
摘要
Tumor metastasis, a leading cause of cancer-related mortality, presents a significant challenge due to its complex, multi-step nature and tumor cells' adaptability. Current targeted therapies often face limitations as tumor cells activate compensatory signaling pathways, leading to drug resistance. Here, we introduce a novel molecular drug pair of sorafenib (Sora) and curcumin (Cur) self-assembled into Sora-Cur@diploid nanoparticles (diNPs), which were transformed into label-free diNP@pharmaceutical dots (diNP@PDs) with enhanced fluorescence through a specialized formulation process, eliminating the need for chemical modification. diNP@PDs exhibit photoluminescence capability, simultaneously promoting cross-talk among lysosomes, mitochondria, and nuclei. This lysosomes-mitochondria-nuclei interaction induces perinuclear clustering of organelles, triggering nuclear reactive oxygen species (nuROS) generation. The nuROS epigenetically suppresses HDAC2 activity, inhibiting epithelial-mesenchymal transition (EMT) and tumor metastasis. By integrating multi-organelle targeting with molecular therapy, diNP@PDs offer an innovative strategy for both imaging and inhibiting tumor metastasis, highlighting the potential of interorganelle approaches in oncology.
科研通智能强力驱动
Strongly Powered by AbleSci AI